GlassScriptPhysician profile
Fadi M Ajine
NPI 1275533986
$5,325.37
in general payments reported to CMS, 2019-2025
24 companies · $647 in 2025
The $647 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $280 · 2021: $1,230 · 2022: $881 · 2023: $725 · 2024: $1,338 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,644 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,644.39 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,473.21 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $981.19 | 2019-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $737.51 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Pfizer INC. | $457.96 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $283.08 | 2019-2025 | |
| Glaxosmithkline, LLC. | $253.08 | 2019-2025 | Benlysta |
| Ucb, INC. | $150.57 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $116.70 | 2021-2024 | Taltz |
| Radius Health, INC. | $115.34 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $85.45 | 2021-2023 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $83.63 | 2020-2024 | Orencia |
| Alexion Pharmaceuticals, INC. | $80.68 | 2019-2022 | |
| Horizon Therapeutics Plc | $74.81 | 2021-2022 | |
| Sandoz INC. | $69.76 | 2024-2025 | Hyrimoz |
| Astrazeneca Pharmaceuticals LP | $65.58 | 2021-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $60.91 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $59.38 | 2021-2022 | |
| Genentech USA, INC. | $58.06 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.67 | 2024 | Cyltezo |
| Celgene Corporation | $24.61 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.59 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.18 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.35 | 2019 | |
| Antares Pharma, INC. | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Ajine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.